Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial)
Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial)
Background: Minimally invasive distal pancreatectomy decreases time to functional recovery compared with open distal pancreatectomy, but the cost-effectiveness and impact on disease-specific quality of life have yet to be established. Methods: The LEOPARD trial randomized patients to minimally invasive (robot-assisted or laparoscopic) or open distal pancreatectomy in 14 Dutch centres between April 2015 and March 2017. Use of hospital healthcare resources, complications and disease-specific quality of life were recorded up to 1 year after surgery. Unit costs of hospital healthcare resources were determined, and cost-effectiveness and cost–utility analyses were performed. Primary outcomes were the costs per day earlier functional recovery and per quality-adjusted life-year. Results: All 104 patients who had a distal pancreatectomy (48 minimally invasive and 56 open) in the trial were included in this study. Patients who underwent a robot-assisted procedure were excluded from the cost analysis. Total medical costs were comparable after laparoscopic and open distal pancreatectomy (mean difference €–427 (95 per cent bias-corrected and accelerated confidence interval €–4700 to 3613; P = 0·839). Laparoscopic distal pancreatectomy was shown to have a probability of at least 0·566 of being more cost-effective than the open approach at a willingness-to-pay threshold of €0 per day of earlier recovery, and a probability of 0·676 per additional quality-adjusted life-year at a willingness-to-pay threshold of €80 000. There were no significant differences in cosmetic satisfaction scores (median 9 (i.q.r. 5·75–10) versus 7 (4–8·75); P = 0·056) and disease-specific quality of life after minimally invasive (laparoscopic and robot-assisted procedures) versus open distal pancreatectomy. Conclusion: Laparoscopic distal pancreatectomy was at least as cost-effective as open distal pancreatectomy in terms of time to functional recovery and quality-adjusted life-years. Cosmesis and quality of life were similar in the two groups 1 year after surgery.
van Hilst, J.
8ebfb3c3-8a12-4a6a-a5fe-b993bfb63d36
Strating, E.A.
364cd2f5-30e6-4c19-ae7a-a53c3935fa8e
de Rooij, T.
f2e3148e-3b0e-4573-99d0-fc4211d687a1
Daams, F.
bfff7bf3-3b8e-400b-bbdc-1dc5183ffe3e
Festen, S.
5b9df6ee-a824-44bc-875b-bcb80875a1b9
Groot Koerkamp, B.
1872bb69-7259-4860-82ae-dbb918f2f301
Klaase, J.M.
1293b147-40a5-47e9-8cf4-631156032cbe
Luyer, M.
6789c7d2-7c22-4b2c-95cb-c468e49151a6
Dijkgraaf, M.G.
0eb6357e-3ddd-4b08-a7ed-01e505c8fa0e
Besselink, M.G.
45b5ed26-b8ed-4706-902f-b36907ed0994
Hilal, M. Abu
384e1c60-8519-4eed-8e92-91775aad4c47
on behalf of the Dutch Pancreatic Cancer Group and LEOPARD trial collaborators
van Hilst, J.
8ebfb3c3-8a12-4a6a-a5fe-b993bfb63d36
Strating, E.A.
364cd2f5-30e6-4c19-ae7a-a53c3935fa8e
de Rooij, T.
f2e3148e-3b0e-4573-99d0-fc4211d687a1
Daams, F.
bfff7bf3-3b8e-400b-bbdc-1dc5183ffe3e
Festen, S.
5b9df6ee-a824-44bc-875b-bcb80875a1b9
Groot Koerkamp, B.
1872bb69-7259-4860-82ae-dbb918f2f301
Klaase, J.M.
1293b147-40a5-47e9-8cf4-631156032cbe
Luyer, M.
6789c7d2-7c22-4b2c-95cb-c468e49151a6
Dijkgraaf, M.G.
0eb6357e-3ddd-4b08-a7ed-01e505c8fa0e
Besselink, M.G.
45b5ed26-b8ed-4706-902f-b36907ed0994
Hilal, M. Abu
384e1c60-8519-4eed-8e92-91775aad4c47
van Hilst, J., Strating, E.A., de Rooij, T., Daams, F., Festen, S., Groot Koerkamp, B., Klaase, J.M., Luyer, M., Dijkgraaf, M.G. and Besselink, M.G.
,
on behalf of the Dutch Pancreatic Cancer Group and LEOPARD trial collaborators
(2019)
Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial).
British Journal of Surgery.
(doi:10.1002/bjs.11147).
Abstract
Background: Minimally invasive distal pancreatectomy decreases time to functional recovery compared with open distal pancreatectomy, but the cost-effectiveness and impact on disease-specific quality of life have yet to be established. Methods: The LEOPARD trial randomized patients to minimally invasive (robot-assisted or laparoscopic) or open distal pancreatectomy in 14 Dutch centres between April 2015 and March 2017. Use of hospital healthcare resources, complications and disease-specific quality of life were recorded up to 1 year after surgery. Unit costs of hospital healthcare resources were determined, and cost-effectiveness and cost–utility analyses were performed. Primary outcomes were the costs per day earlier functional recovery and per quality-adjusted life-year. Results: All 104 patients who had a distal pancreatectomy (48 minimally invasive and 56 open) in the trial were included in this study. Patients who underwent a robot-assisted procedure were excluded from the cost analysis. Total medical costs were comparable after laparoscopic and open distal pancreatectomy (mean difference €–427 (95 per cent bias-corrected and accelerated confidence interval €–4700 to 3613; P = 0·839). Laparoscopic distal pancreatectomy was shown to have a probability of at least 0·566 of being more cost-effective than the open approach at a willingness-to-pay threshold of €0 per day of earlier recovery, and a probability of 0·676 per additional quality-adjusted life-year at a willingness-to-pay threshold of €80 000. There were no significant differences in cosmetic satisfaction scores (median 9 (i.q.r. 5·75–10) versus 7 (4–8·75); P = 0·056) and disease-specific quality of life after minimally invasive (laparoscopic and robot-assisted procedures) versus open distal pancreatectomy. Conclusion: Laparoscopic distal pancreatectomy was at least as cost-effective as open distal pancreatectomy in terms of time to functional recovery and quality-adjusted life-years. Cosmesis and quality of life were similar in the two groups 1 year after surgery.
Text
Hilst et al 2019 British Journal of Surgery
- Version of Record
More information
Accepted/In Press date: 1 February 2019
e-pub ahead of print date: 23 April 2019
Identifiers
Local EPrints ID: 431265
URI: http://eprints.soton.ac.uk/id/eprint/431265
ISSN: 0007-1323
PURE UUID: c413397a-d579-4502-8100-855c81a6d5e0
Catalogue record
Date deposited: 29 May 2019 16:30
Last modified: 16 Mar 2024 02:04
Export record
Altmetrics
Contributors
Author:
J. van Hilst
Author:
E.A. Strating
Author:
T. de Rooij
Author:
F. Daams
Author:
S. Festen
Author:
B. Groot Koerkamp
Author:
J.M. Klaase
Author:
M. Luyer
Author:
M.G. Dijkgraaf
Author:
M.G. Besselink
Author:
M. Abu Hilal
Corporate Author: on behalf of the Dutch Pancreatic Cancer Group and LEOPARD trial collaborators
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics